First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial

Association Between Steroid-Sparing Therapy and the Risk of Perianal Fistulizing Complications Among Young Patients With Crohn Disease

(2020) Jeremy Adler et al.   JAMA Network Open

P083 VALIDATION OF A NEW PHYSICIAN GLOBAL ASSESSMENT COLONOSCOPY SCORE (PGA-CS) FOR PEDIATRIC CROHN’S DISEASE

(2019) Jeremy Adler et al.   INFLAMMATORY BOWEL DISEASES

Complicated Disease and Response to Initial Therapy Predicts Early Surgery in Paediatric Crohn’s Disease: Results From the Porto Group GROWTH Study

(2019) Arie Levine et al.   Journal of Crohns & Colitis

Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease

(2019) David R. Mack et al.   GASTROENTEROLOGY

Cost-effectiveness and Clinical Outcomes of Early Anti–Tumor Necrosis Factor–α Intervention in Pediatric Crohn’s Disease

(2019) Naazish S Bashir et al.   INFLAMMATORY BOWEL DISEASES

Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn’s Disease in Sustained Remission

(2018) Catherine Reenaers et al.   Clinical Gastroenterology and Hepatology

Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn’s disease

(2018) Tomer Ziv-Baran et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease

(2017) Jeffrey S. Hyams et al.   GASTROENTEROLOGY

Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study

(2017) Subra Kugathasan et al.   LANCET

Mucosal Healing in Paediatric Patients with Moderate-to-Severe Luminal Crohn’s Disease Under Combined Immunosuppression: Escalation versus Early Treatment

(2016) Ben Kang et al.   Journal of Crohns & Colitis

Infliximab “Top-Down” Strategy is Superior to “Step-Up” in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease

(2015) Yoo Min Lee et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy

(2014) Filip Baert et al.   Clinical Gastroenterology and Hepatology

Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease

(2014) F.M. Ruemmele et al.   Journal of Crohns & Colitis

Increased Effectiveness of Early Therapy With Anti-Tumor Necrosis Factor-α vs an Immunomodulator in Children With Crohn's Disease

(2013) Thomas D. Walters et al.   GASTROENTEROLOGY

The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn’s disease

(2012) Jarosław Kierkus et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Mathematical weighting of the pediatric Crohnʼs disease activity index (PCDAI) and comparison with its other short versions

(2011) Dan Turner et al.   INFLAMMATORY BOWEL DISEASES

Infliximab therapy in children with Crohn’s disease: a one-year evaluation of efficacy comparing ‘top-down’ and ‘step-up’ strategies

(2010) Mi Jin Kim et al.   ACTA PAEDIATRICA

Endoscopic monitoring of infliximab therapy in Crohnʼs disease

(2010) Clas-Göran af Björkesten et al.   INFLAMMATORY BOWEL DISEASES

Pediatric modification of the Montreal classification for inflammatory bowel disease

(2010) Arie Levine et al.   INFLAMMATORY BOWEL DISEASES

Efficacy of early treatment with infliximab in pediatric Crohn’s disease

(2010) Jong Seung Lee   WORLD JOURNAL OF GASTROENTEROLOGY

Natural history of Crohnʼs disease

(2009) Bénédicte Pigneur et al.   INFLAMMATORY BOWEL DISEASES

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET